- Case report
- Open Access
- Open Peer Review
Fatal anti-aquaporin-4 seropositive neuromyelitis optica spectrum disorder in tuberculosis
© Sridhar et al.; licensee BioMed Central Ltd. 2014
- Received: 2 May 2014
- Accepted: 18 August 2014
- Published: 28 August 2014
Neuromyelitis optica (NMO) is an autoimmune inflammatory condition of the central nervous system that is characterized by circulating anti-aquaporin-4 antibodies, transverse myelitis and optic neuritis. NMO spectrum disorders are rarely reported in patients with active pulmonary tuberculosis (TB). We report a fatal case of anti-aquaporin-4 antibody positive NMO spectrum disorder in a patient who was receiving treatment for pulmonary tuberculosis.
A previously healthy 42-year-old Chinese man was diagnosed with smear positive pulmonary tuberculosis. After one month of anti-tuberculosis treatment, he presented with acute generalized weakness and rapid neurological deterioration. Spinal imaging and anti-aquaporin-4 antibody positivity established a diagnosis of neuromyelitis optica spectrum disorder.
This is the first reported case of anti-aquaporin-4 antibody-positive NMO spectrum disorder in a patient with active tuberculosis. It shows the usefulness of testing for anti-aquaporin-4 antibodies while evaluating neurological deterioration in patients with tuberculosis. The literature on the rare association between NMO spectrum disorders and TB is reviewed.
- Neuromyelitis optica
- Anti-aquaporin-4 antibody
Neuromyelitis optica is an autoimmune inflammatory disorder of the central nervous system affecting the optic nerves and the spinal cord, manifesting as recurrent episodes of longitudinally extensive transverse myelitis (LETM) and/or optic neuritis. Previously classified as a subtype of multiple sclerosis, NMO is now considered to be a distinct clinical, pathological, and immunological entity . A key diagnostic test for NMO spectrum disorders is the presence of anti-aquaporin-4 (anti-Aqp-4) IgG antibodies in patient serum . Aquaporin-4 is a membrane water channel that is most abundant at astrocytic end-feet. Anti-Aqp-4 IgG has been found to be a highly specific marker for the NMO spectrum disorders that include classic NMO, isolated optic neuritis, isolated LETM, and isolated brain stem encephalitis [3–6]. This test now forms part of the diagnostic criteria for neuromyelitis optica .
A small number of case reports describe patients developing NMO like syndromes shortly after being diagnosed with pulmonary tuberculosis, hinting at a rare association between the two entities [7–9]. Despite the shortcomings of case–control studies in elucidating rare associations between exposures and disease, two groups have conducted case–control studies comparing the prevalence of TB between NMO patients and control patients with other neurological diagnoses. While one study found a significant association between NMO and TB in a high TB – low NMO prevalence setting in South Africa, another study in an intermediate TB – high NMO prevalence setting in southern China failed to demonstrate a significant association [10, 11]. However, a clinical trial conducted in another Chinese NMO patient group demonstrated a marked beneficial effect of anti-TB treatment on the course of patients with steroid refractory NMO even in the absence of overt tuberculosis suggesting a possible association of latent TB with NMO that would have been missed in the case–control studies . Therefore, the evidence to date is in favor of an association with TB in a subset of NMO patients, who may benefit from anti-TB treatment. None of the patients with TB associated NMO-like disorder described previously have been shown to have anti-Aqp-4 antibodies.
We report a rapidly progressive and fatal case of anti-Aqp-4 antibody-positive neuromyelitis optica (NMO) like disorder in a patient receiving treatment for pulmonary TB. To the best of our knowledge, our case is the first report of anti-Aqp-4 antibody-positive NMO like disorder in a patient with active pulmonary TB. The rapidity of our patient’s deterioration is also unprecedented in the published literature on TB-associated NMO.
From our case report and other cases in the literature, NMO appears to develop shortly after the diagnosis of pulmonary TB even when the patient is started on appropriate anti-TB medications. We show that anti-Aqp-4 antibodies are present in TB associated NMO; these antibodies are known to play a pathogenic role in NMO . The mechanism by which TB infection triggers the formation of these antibodies is uncertain. Mycobacterium tuberculosis surface antigens may trigger the formation of cross-reactive antibodies against aquaporin-4 channel proteins. However, immunity against active TB infection is generally geared towards a cell-mediated immune response rather than a humoral response, therefore the contribution of this mechanism is uncertain. Further research is required to elucidate the biological basis for this association.
In summary, this case highlights NMO like disorder as a fatal immunological complication of TB and illustrates the diagnostic role of anti-Aqp-4-antibody in patients with active TB and concomitant neurological deterioration.
The patient’s condition deteriorated rapidly with high fever, hypotension, and coma. He was intubated and vasopressor support was commenced. A plain computed tomography scan of the brain was unremarkable. Lumbar puncture showed clear cerebrospinal fluid (CSF) with an elevated opening pressure of 20 cmH2O. Total cell count of the CSF was elevated to 62×106/l with neutrophil predominance. CSF and peripheral blood glucose levels were 1.1 mmol/l and 4.9 mmol/l respectively, and CSF protein was elevated to >6 mmol/l. Gram-stained and Ziehl-Neelsen-stained smears of the CSF showed no organism. Culture of the CSF yielded no bacterial, mycobacterial, and fungal growth. Molecular tests including TB-PCR, HSV-PCR, and enterovirus RT-PCR were negative.
A diagnosis of disseminated TB with central nervous system involvement was made. As the patient’s condition had deteriorated despite four weeks of first line anti-tuberculous drugs, multidrug-resistant TB was suspected. The drug regimen was changed to intravenous rifampicin 450 mg q24 h, ethambutol 1200 mg q24 h, levofloxacin 500 mg q24 h, linezolid 600 mg q24 h, and amikacin 750 mg q24 h. The patient was also given a combination of intravenous meropenem 1000 mg q8 h and intravenous amoxicillin-clavulanate 1200 mg q12 h for broad-spectrum antibacterial and anti-tuberculous coverage [13, 14]. Intravenous dexamethasone was also started at 4 mg q8 h . Genotypic testing for drug resistance using a line probe assay (GenoType MTBDRplus, Hain Lifescience) on the M. tuberculosis isolate from the patient’s first admission was negative for the common isoniazid and rifampicin resistance mutations (katG, inhA and rpoB respectively). An underlying immunological defect was considered in view of the clinical deterioration despite in-vitro drug susceptibility. The combined HIV-antigen/antibody test and anti-interferon-gamma autoantibody were negative [16, 17].
Due to the radiological finding of LETM, the neuromyelitis optica (NMO) spectrum disorders were a diagnostic consideration. Serum anti-aquaporin-4 (anti-Aqp-4) antibodies were positive by an immunofluorescence assay (Euroimmun). The patient was diagnosed with NMO spectrum disorder complicating active pulmonary TB without evidence of mycobacterial central nervous system infection. Despite treatment with corticosteroid, the patient’s condition further deteriorated with severe hyperthermia, high ventilatory requirement, loss of brainstem reflexes, and labile hemodynamic status. He died after thirteen days of admission.
In summary, our case highlights NMO like disorders as an important diagnostic consideration in patients with active TB who present with acute neurological disorders. Serum anti-Aqp-4 antibodies should be part of the diagnostic workup of patients with active TB who present with transverse myelitis and/or optic neuritis. Further multicenter trials are required to clarify the etiological role of TB in triggering NMO like disorders.
Written informed consent was obtained from the patient’s next of kin (brother) for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
This work is partly supported by the Health Medical Research Fund of Food & Health Bureau of Hong Kong Government (Ref: 13121342).
- Barnett MH, Sutton I: Neuromyelitis optica: not a multiple sclerosis variant. Curr Opin Neurol. 2012, 25: 215-220. 10.1097/WCO.0b013e3283533a3f.View ArticlePubMedGoogle Scholar
- Morrow MJ, Wingerchuk D: Neuromyelitis optica. J Neuroophthalmol. 2012, 32: 154-166. 10.1097/WNO.0b013e31825662f1.View ArticlePubMedGoogle Scholar
- Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG: A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004, 364: 2106-2112. 10.1016/S0140-6736(04)17551-X.View ArticlePubMedGoogle Scholar
- Chan KH, Kwan JS, Ho PW, Ho JW, Chu AC, Ramsden DB: Aquaporin-4 autoantibodies in neuromyelitis optica spectrum disorders: comparison between tissue-based and cell-based indirect immunofluorescence assays. J Neuroinflammation. 2010, 7: 50-10.1186/1742-2094-7-50.View ArticlePubMedPubMed CentralGoogle Scholar
- Jacob A, McKeon A, Nakashima I, Sato DK, Elsone L, Fujihara K, de Seze J: Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2013, 84: 922-930. 10.1136/jnnp-2012-302310.View ArticlePubMedGoogle Scholar
- Chan KH, Tse CT, Chung CP, Lee RL, Kwan JS, Ho PW, Ho JW: Brain involvement in neuromyelitis-optica spectrum disorders. Arch Neurol. 2011, 68: 1432-1439. 10.1001/archneurol.2011.249.View ArticlePubMedGoogle Scholar
- Rafai MA, Boulaajaj FZ, Gynerane M, El Moutawakkil B, Slassi I: Devic-like syndrome in the course of pulmonary tuberculosis. Acta Neuro Belg. 2010, 110: 196-200.Google Scholar
- Siddiqi SA, Hashmi M, Azmat Z, Mustafa S, Siddiqui KA: Pulmonary tuberculosis with Neuromyelitis Optica: an uncommon association of a common disease. J Coll Physicians Surg Pak. 2012, 22: 527-528.PubMedGoogle Scholar
- Silber MH, Willcox PA, Bowen RM, Unger A: Neuromyelitis optica (Devic’s syndrome) and pulmonary tuberculosis. Neurology. 1990, 40: 934-938. 10.1212/WNL.40.6.934.View ArticlePubMedGoogle Scholar
- Zatjirua V, Butler J, Carr J, Henning F: Neuromyelitis optica and pulmonary tuberculosis: a case–control study. Int J Tuberc Lung Dis. 2011, 15: 1675-1680. 10.5588/ijtld.10.0780.View ArticlePubMedGoogle Scholar
- Li R, Zhong X, Qiu W, Wu A, Dai Y, Lu Z, Hu X: Association between neuromyelitis optica and tuberculosis in a Chinese population. BMC Neurol. 2014, 14: 33-10.1186/1471-2377-14-33.View ArticlePubMedPubMed CentralGoogle Scholar
- Feng YQ, Guo N, Huang F, Chen X, Sun QS, Liu JX: Anti-tuberculosis treatment for Devic’s neuromyelitis optica. J Clin Neurosci. 2010, 17 (11): 1372-1377. 10.1016/j.jocn.2010.02.023.View ArticlePubMedGoogle Scholar
- De Lorenzo S, Alffenaar JW, Sotqiu G, Centis R, D’Ambrosio L, Tiberi S, Bolhuis MS, van Altena R, Viggiani P, Piana A, Spanevello A, Migliori GB: Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J. 2013, 41: 1386-1392. 10.1183/09031936.00124312.View ArticlePubMedGoogle Scholar
- England K, Boshoff HI, Arora K, Weiner D, Dayao E, Schimel D, Via LE, Barry CE: Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother. 2012, 56: 3384-3387. 10.1128/AAC.05690-11.View ArticlePubMedPubMed CentralGoogle Scholar
- Thwaites G, Fisher M, Hemingway C, Scott G, Solomon T, Innes J: British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect. 2009, 59: 167-187. 10.1016/j.jinf.2009.06.011.View ArticlePubMedGoogle Scholar
- Tang BS, Chan JF, Chen M, Tsang OT, Mok MY, Lai RW, Lee R, Que TL, Tse H, Li IW, To KK, Cheng VC, Chan EY, Zheng B, Yuen KY: Disseminated penicilliosis, recurrent bacteremic nontyphoidal salmonellosis, and burkholderiosis associated with acquired immunodeficiency due to autoantibody against gamma interferon. Clin Vaccine Immunol. 2010, 17: 1132-1138. 10.1128/CVI.00053-10.View ArticlePubMedPubMed CentralGoogle Scholar
- Chan JF, Trendell-Smith NJ, Chan JC, Hung IF, Tang BS, Cheng VC, Yeung CK, Yuen KY: Reactive and infective dermatoses associated with adult-onset immunodeficiency due to anti-interferon-gamma autoantibody: Sweet’s syndrome and beyond. Dermatology. 2013, 226: 157-166. 10.1159/000347112.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/14/470/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.